Subscribe To
Ubisoft tipped for a boost, if thursday's update confirms pipeline is on-track
Ubisoft's investment appeal is “compelling at current levels”, according to analysts at Wedbush, who repeated an ‘outperform' rating ahead of ...
October 23, 2023, 10:59 am
Potential of arvinas’ protac® ar degraders reinforced by 11.1 months rpfs with bavdegalutamide and updated positive interim data from second generation arv-766 in mcrpc
– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progress...
October 22, 2023, 11:00 am
Harpoon therapeutics announces updated interim tolerability and response data from phase 1/2 clinical trial of t cell engager hpn328 at esmo congress 2023
Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete re...
October 21, 2023, 3:31 pm
Gold price forecast: $1,860-$1,960 range to hold amid slightly heightened volatility – ocbc
In the interim, geopolitical situation in Israel-Hamas should pose two-way risks to Gold prices. Escala...
October 19, 2023, 3:44 pm
Excision biotherapeutics announces presentation of interim clinical data for ebt-101 in latent hiv at upcoming european society of gene and cell therapy (esgct) 2023 annual congress
SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based thera...
October 19, 2023, 11:50 am
Location, location, location: bradda head's ian stalker talks lithium in the usa
It may turn out that Ian Stalker is only in an executive role at Bradda Head for a short period of time. Certainly, the announcement of his assumption...
October 19, 2023, 8:05 am
Whitbread results pave way for further upgrades, says city analysts
Whitbread PLC (LSE:WTB) impressed at its interims and the results have gone down well in the City with...
October 18, 2023, 8:34 am
Hipgnosis songs fund meeting to face objections from major shareholders
Analysts and a major investor say that the upcoming Hipgnosis Songs Fund Limited (LSE:SONG) shareholder meeting might echo the Ella Fitzgerald song ...
October 17, 2023, 9:56 am
Can wework's new permanent ceo save we stock?
WeWork (NYSE: WE ) stock rose after naming board member David Tolley its permanent CEO. Tolley had been inter...
October 16, 2023, 10:42 am
Wework appoints david tolley as permanent chief executive
WeWork Inc (NYSE:WE) has appointed David Tolley as its new chief executive officer. Tolley has been on the WeWork board since February and has been ...
October 16, 2023, 9:13 am
Wework makes david tolley permanent ceo
WeWork Inc. WE, +3.96% said Monday it has promoted interim Chief Executive David Tolley to the role of ...
October 16, 2023, 8:39 am
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous a...
October 14, 2023, 8:30 pm